Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. Its product categories include HIV, COVID-19, Viral Hepatitis, Oncology and others. Under HIV, it offers Biktarvy, Genvoya, Descovy, Odefsey, Complera /Eviplera, Truvada, Stribild and Sunlenca. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of COVID-19. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / Chronic hepatitis delta virus (Vemlidy and Viread). Under oncology, it offers cell therapy containing Tecartus and Yescarta. Its other products include AmBisome and Letairis. Biktarvy is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients.

  • Revenue in USD (TTM)27.12bn
  • Net income in USD5.66bn
  • Incorporated1987
  • Employees18.00k
  • Location
    Gilead Sciences Inc333 LAKESIDE DRFOSTER CITY 94404United StatesUSA
  • Phone+1 (650) 574-3000
  • Fax+1 (650) 578-9264
  • Websitehttps://www.gilead.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
GILD:NSQ since
announced
Transaction
value
XinThera IncDeal completed09 May 202309 May 2023Deal completed-6.78%--
Data delayed at least 15 minutes, as of Mar 18 2024 20:00 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.